NASDAQ:RNXT

Renovorx Stock Insider Trading

Healthcare > Biotechnology

Buy RNXT

*Your capital is at risk

$0.91

-0.0049 (-0.538%)

At Close: Jun 03, 2026

RenovoRx Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 5.98M and sold 800K RNXT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	5.98M shares
● Sell	800K shares
98% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Apr 06, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 100. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (98% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 19, 2026 Buy	Common Stock P-Purchase	Voll Mark Chief Financial Officer	C-Suite Officer	25 000 Value: $19.7K
Apr 03, 2026 Buy	Stock Option A-Award	Agah Ramtin Chief Medical Officer	Officer	621 727 Value: $609.3K
Apr 03, 2026 Buy	Stock Option A-Award	Gentry Leesa Chief Clinical Officer	Officer	128 550 Value: $126.0K
Apr 03, 2026 Buy	Common Stock A-Award	Voll Mark Chief Financial Officer	C-Suite Officer	80 000 Value: $72.4K
Apr 03, 2026 Buy	Stock Option A-Award	Bagai Shaun Chief Executive Officer	CEO / President	946 107 Value: $927.2K
Mar 25, 2026 Buy	Common Stock A-Award	Voll Mark Chief Financial Officer	C-Suite Officer	12 380 Value: $13.6K
Mar 20, 2026 Buy	Warrants P-Purchase	Voll Mark Chief Financial Officer	C-Suite Officer	48 600 Value: $93.9K
Mar 20, 2026 Buy	Common Stock P-Purchase	Voll Mark Chief Financial Officer	C-Suite Officer	97 200 Value: $97.2K
Mar 20, 2026 Buy	Warrants P-Purchase	Bagai Shaun Chief Executive Officer	CEO / President	12 150 Value: $23.5K
Mar 20, 2026 Buy	Common Stock P-Purchase	Bagai Shaun Chief Executive Officer	CEO / President	24 300 Value: $24.3K
Mar 20, 2026 Buy	Warrants P-Purchase	Marton Laurence Director	Director	4 860 Value: $9K
Mar 20, 2026 Buy	Common Stock P-Purchase	Marton Laurence Director	Director	9 720 Value: $10K
Feb 04, 2026 Buy	Common Stock	Voll Mark Chief Financial Officer	C-Suite Officer	0 Value: $0
Jan 21, 2026 Buy	Common Stock P-Purchase	Agah Ramtin Chief Medical Officer	Officer	10 000 Value: $10K
Dec 31, 2025 Buy	Common Stock P-Purchase	Agah Ramtin Chief Medical Officer	Officer	9 795 Value: $8K
Dec 30, 2025 Buy	Common Stock P-Purchase	Agah Ramtin Chief Medical Officer	Officer	205 Value: $169
Dec 18, 2025 Buy	Common Stock P-Purchase	Bagai Shaun Chief Executive Officer	CEO / President	5 000 Value: $5K
Dec 17, 2025 Buy	Common Stock P-Purchase	Bagai Shaun Chief Executive Officer	CEO / President	5 000 Value: $4K
Dec 16, 2025 Buy	Common Stock P-Purchase	Agah Ramtin Chief Medical Officer	Officer	12 000 Value: $10.2K
Dec 05, 2025 Buy	Common Stock P-Purchase	Agah Ramtin Chief Medical Officer	Officer	10 000 Value: $10K
Nov 24, 2025 Buy	Common Stock P-Purchase	Agah Ramtin Chief Medical Officer	Officer	12 000 Value: $10K
Nov 21, 2025 Buy	Common Stock P-Purchase	Agah Ramtin Chief Medical Officer	Officer	10 000 Value: $8K
Oct 01, 2025 Buy	Stock Options (right to buy) A-Award	Marton Laurence Director	Director	47 640 Value: $63.8K
Oct 01, 2025 Buy	Stock Options (right to buy) A-Award	Marton Laurence Director	Director	47 640 Value: $63.8K
Oct 01, 2025 Buy	Stock Options (right to buy) A-Award	Macfarlane K. Angela Director	Director	47 640 Value: $63.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RENOVORX, INC.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California....

Read Full Profile Here